围手术期是否应停用抗血小板治疗?首项探讨下肢游离皮瓣患者接受双联抗血小板治疗结局的研究
回顾性分析2011至2019年由资深作者完成的195例下肢游离组织移植,其中34例使用氯吡格雷(20例停药、14例继续)。停药组与继续组输血发生率均高于非氯吡格雷组;皮瓣成功率三组间无显著差异(90.0% vs 92.9% vs 95.0%,p=0.346);心脏事件在继续组最多(21.4%)。作者认为围手术期双联抗血小板治疗下可安全完成游离组织移植。
要点
- 下肢游离皮瓣患者围手术期使用双联抗血小板治疗,皮瓣成功率三组间无显著差异(p=0.346)。
- 停药组与继续组输血发生率均高于非氯吡格雷组;多因素分析显示停用氯吡格雷与术后输血 odds 增加独立相关。
- 继续双联抗血小板治疗未减少术中输血,作者认为可全程继续以降低心血管风险。
核心结论
- 尽管输血量增加,围手术期双联抗血小板治疗下可安全完成游离组织移植。
- 游离组织移植当天停用双联抗血小板治疗未与术中输血减少相关,作者认为可全程继续双联抗血小板治疗以最小化心血管风险。
研究设计与样本
- 回顾性研究,纳入2011至2019年由资深作者(K.K.E.)完成的下肢游离组织移植195例。
- 记录人口学、合并症、围手术期双联抗血小板治疗及游离组织移植特征。
- 关注结局包括皮瓣成功、血肿形成、输血需求和心脏事件发生。
- 证据等级:治疗性,III级。
主要发现
- 游离组织移植时中位年龄56.5岁,中位Charlson合并症指数为3。
- 34例患者使用氯吡格雷,其中20例在游离组织移植当天停药、14例继续用药。
- 输血发生率在停药组和继续组均显著高于非氯吡格雷组。
- 皮瓣成功率三组间统计学等效:停药组90.0%、继续组92.9%、非氯吡格雷组95.0%(p=0.346)。
- 心脏事件在继续组发生率最高(21.4%),停药组为5.0%,非氯吡格雷组为0.6%;多因素分析中停用氯吡格雷与术后输血 odds 增加仍显著相关,氯吡格雷组与术中输血的关联不再显著。
临床怎么用
- 作者认为,尽管血制品输注量增加,围手术期双联抗血小板治疗下可安全进行游离组织移植。
- 作者认为,游离组织移植当天停用双联抗血小板治疗未与术中输血减少相关,可全程继续双联抗血小板治疗以最小化心血管风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiplatelet agents are typically withheld perioperatively because of bleeding concerns. Dual antiplatelet therapy, such as aspirin and clopidogrel, has significant morbidity and mortality benefits in patients with ischemic heart disease or peripheral vascular disease. This study aims to evaluate the impact of perioperative dual antiplatelet therapy in the lower extremity free tissue transfer population. METHODS: Lower extremity free tissue transfers performed by the senior author (K.K.E.) from 2011 to 2019 were retrospectively reviewed. Demographics, comorbidities, perioperative dual antiplatelet therapy, and free tissue transfer characteristics were recorded. Outcomes of interest included flap success, hematoma formation, blood transfusion requirements, and cardiac event occurrence. RESULTS: One hundred ninety-five free tissue transfers were included. Median age at the time of free tissue transfer was 56.5 years. Median Charlson Comorbidity Index was 3. Thirty-four patients were on clopidogrel, which was either withheld (n = 20) or continued (n = 14) on the day of free tissue transfer. Incidence of blood transfusion was significantly higher in both the withheld and continued versus nonclopidogrel groups. Flap success was statistically equivalent between groups (withheld, 90.0 percent; continued, 92.9 percent; nonclopidogrel, 95.0 percent; p = 0.346). Cardiac events occurred most often in the continued group (21.4 percent) compared to the withheld (5.0 percent) and nonclopidogrel (0.6 percent) groups. On multivariate analysis, holding clopidogrel remained significant for increased odds of postoperative transfusion. The clopidogrel group was no longer significant for intraoperative transfusion. CONCLUSIONS: Despite increases in volume of blood products transfused, free tissue transfer can be performed safely with perioperative dual antiplatelet therapy. Withholding dual antiplatelet therapy on the day of free tissue transfer was not associated with decreased intraoperative transfusion; thus, dual antiplatelet therapy can safely be continued throughout the operative course to minimize cardiovascular risk. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Mishu MD, Zolper EG, Dekker PK, et al. Should Antiplatelet Therapy Be Withheld Perioperatively? The First Study Examining Outcomes in Patients Receiving Dual Antiplatelet Therapy in the Lower Extremity Free Flap Population. Plast Reconstr Surg. 2022. PMID: 34936629. doi:10.1097/PRS.0000000000008666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。